- Home
- GAME vs BTAI Comparison
GAME vs BTAI Comparison
Compare GAME & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GAME | BTAI |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.4M | 34.9M |
| IPO Year | 2024 | 2018 |
Fundamental Metrics
Financial Performance| Metric | GAME | BTAI |
|---|---|---|
| Price | $0.40 | $1.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | ★ 1.9M | 582.9K |
| Earning Date | 04-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 65.14 | ★ 75.63 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $44,999,302.00 | N/A |
| Revenue This Year | $87.12 | $197.82 |
| Revenue Next Year | $21.14 | $910.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.24 | $1.01 |
| 52 Week High | $2.87 | $8.08 |
Technical Indicators
Market Signals| Indicator | GAME | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 46.30 | 61.76 |
| Support Level | $0.26 | $1.02 |
| Resistance Level | $0.49 | $1.37 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 28.93 | 72.46 |
Price Performance
Historical ComparisonAbout GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is a vertically integrated digital media, entertainment, and technology company focused on gaming and youth culture audiences. The company operates through four reportable segments: Owned and Operated IP, Agency, SaaS and managed services, and Yield. It provides services including influencer marketing, esports talent management, creative production, merchandise and consumer products, live streaming analytics, and digital media solutions through its various brands and platforms. It generates the majority of its revenue from the Agency segment.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.